{
    "symbol": "AUVI",
    "quarter": 4,
    "year": 2022,
    "date": "2023-04-03 11:17:05",
    "content": " Net sales of $2.01 million represented an increase of $8.5 million or 73% for the year ended December 31, 2022 as compared to net sales of $11.6 million for the prior year. The pathogen elimination and disinfection segment had sales of $6.5 million in 2022, which represented a 14% increase over the prior year. Gross profit was $4.0 million, which is approximately 20% of sales the year ended December 31, 2022, as compared to $4.1 million or approximately 35% of sales for the prior year. SG&A costs were $14.8 million for the year ended December 31, 2022, which represented an increase of $3.5 million as compared to the prior year. And as a result, the company recorded a full non cash goodwill impairment charge of $1.1 million on the consolidated statements of operations for the year ended December 31, 2022. As a result of our analysis, an additional non cash impairment of intangibles of $5.9 million was also recorded in the consolidated statements of operations for the year ended December 31, 2022. As a result of the Scientific Air settlement and the change in the values of the shares of stock returned to the company, the company recorded a net gain of $1.4 million in other income in the year ended December 31, 2022. The company recorded a net loss of $16.6 million for the year ended December 31, 2022 compared to a net loss of $7.4 million for the prior year."
}